

FREE

ARVO Annual Meeting Abstract | April 2014

# Six months study on signs and symptoms of polyquad preserved travoprost/timolol fixed combination on previously treated glaucoma patients.

Teresa Rolle; Rachele R Penna; Laura Dallorto; Fiamma Campana; Luigia Scudeller; Sara Lanteri; Gemma C Rossi

[+ Author Affiliations & Notes](#)

Investigative Ophthalmology &amp; Visual Science April 2014, Vol.55, 2916. doi:

## Abstract

**Purpose:** To assess usefulness and tolerability of switching glaucoma patients to the fixed combination Travoprost 0.004%/Timolol 0.5% with polyquad (PQ-TTFC); to record effects on tear film break-up time (TF-BUT) and on quality of life (OSDI).

**Methods:** Multicenter, observational cohort, 6 month study. 50 patients on concomitant Timolol 0.5% (twice a day) and Dorzolamide (twice a day) or Timolol and Latanoprost (once a day) (BAK-preserved) were switched to PQ-TTFC (evening dosage). IOP, TFBUT and AEs were recorded and all patients completed the OSDI questionnaire at baseline and after 6 months. All analysis refers to right eye; left eye's data are similar.

**Results:** Median age was 70 [63-73] years, women were 54.9% of the sample. IOP significantly decreased (from 18 [16-21] to 15 [12-17] mmHg) after substitution ( $p < 0.001$ ). At baseline 31.4% of patients presented an IOP  $< 18$  mmHg, the percentage increased to 80% of subjects at 6 months ( $p < 0.001$ ). TF-BUT improved of  $2.7 \pm 1.9$  sec (from 7 [5-8] to 10 [9-11] sec,  $p < 0.001$ ). Only one patient discontinued the new therapy due to periocular skin pigmentation. Quality of life improved from 28 (moderate) to 19 (mild) ( $p < 0.001$ ).

**Conclusions:** PQ-TTFC appeared useful in this selected population: patients who underwent a regimen modification to PQ-TTFC obtained further reduction in IOP; improvement in ocular surface status with no exposition to BAK toxicity; and reported a better quality of life perception. The low discontinuation's rate at 6 months indicates a good tolerability profile.

**Keywords:** 568 intraocular pressure • 503 drug toxicity/drug effects • 669 quality of life

© 2014, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.